Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Preclinical Evaluation for Engraftment of Gene-Edited CD34+ Cells with a Sickle Cell Disease Mutation in a Rhesus Transplantation Model

Naoya Uchida, MD, Linhong Li, PhD, Tina Nassehi, Morgan Yapundich, Jackson Gamer, Claire Drysdale, Juan J. Haro-Mora, PhD, Selami Demirci, PhD, Aylin Bonifacino, MS, Allen Krouse, Nathaniel S. Linde, Cornell Allen, MS, Suk See De Ravin, MD, PhD, Robert E. Donahue, VMD, Harry L. Malech, MD, Madhusudan Peshwa, PhD, John F. Tisdale, MD

Blood (2019) 134 (Supplement_1): 609.

https://doi.org/10.1182/blood-2019-122727

Published: 2019

Journal Articles

Gene Editing and mRNA-Based Therapy: Two Complementary Therapeutic Approaches for the Treatment of Patients with Xmen Disease

Julie Brault, PhD PharmD, Ezekiel Bello, Ronald J. Meis, PhD, Taylor Liu, Sherry M. Koontz, BS, Kennichi Dowdell, PhD, Linhong Li, PhD, Cornell Allen, MS, Narda Theobald, BS, Janet Lee, BS, Aaron B. Clark, BS, Juan C. Ravell, MD, Michael Lenardo, MD, Gary A. Dahl, PhD, Harry L. Malech, MD, Suk See De Ravin, MD, PhD

Blood (2019) 134 (Supplement_1): 4637.

https://doi.org/10.1182/blood-2019-129062

Published: 2019

Journal Articles

A Highly Efficient, Clinically Applicable Transfection Method to Redirect the Specificity of Immune Cells and Enhance Their Anti-Tumor Capacity

Linhong Li, PhD, Lawrence Wolfraim, PhD, Cornell Allen, Angelia Viley, Hiroyuki Fujisaki, Dario Campana, MD., PhD, Joseph C. Fratantoni, MD, Madhusudan V Peshwa, PhD

Blood (2008) 112 (11): 3894.

https://doi.org/10.1182/blood.V112.11.3894.3894

Published: 2008

Journal Articles

Vaccination Strategies for Patients with B-CLL.

Fatma V Okur, MD, Eric Yvon, MS, Gianpietro Dotti, MD, George Carrum, MD, Helen E. Heslop, MD, Malcolm K Brenner, MD, PhD, Joseph C. Fratantoni, MD, Madhusudan V Peshwa, PhD, Linhong Li, PhD

Blood (2008) 112 (11): 2106.

https://doi.org/10.1182/blood.V112.11.2106.2106

Published: 2008

Journal Articles

An Improved, Non-Viral Approach for Production of hCD40L + B-CLL Cells for Cancer Immunotherapy.

Linhong Li, PhD, Cornell Allen, MS, Stephanie Feller, MS, Larry Wolfraim, PhD, Angelia Viley, MS, Joseph C. Fratantoni, MD, Linda N. Liu, PhD

Blood (2006) 108 (11): 2107.

https://doi.org/10.1182/blood.V108.11.2107.2107

Published: 2006

Journal Articles

A Practical Approach for Achieving Clinical Immunotherapy of CLL with hCD40L- and hIL-2-Expressing Autologous Tumor Cells.

Joseph C. Fratantoni, MD, Linhong Li, PhD, Linda N. Liu, PhD, Madhusudan V. Peshwa, PhD, Malcolm Brenner, MD, PhD, Eric Yvon, MS, George Carrum, MD, Ettore Biagi, MD

Blood (2005) 106 (11): 450.

https://doi.org/10.1182/blood.V106.11.450.450

Published: 2005

NARROW

Preclinical Evaluation for Engraftment of Gene-Edited CD34+ Cells with a Sickle Cell Disease Mutation in a Rhesus Transplantation Model

Gene Editing and mRNA-Based Therapy: Two Complementary Therapeutic Approaches for the Treatment of Patients with Xmen Disease

A Highly Efficient, Clinically Applicable Transfection Method to Redirect the Specificity of Immune Cells and Enhance Their Anti-Tumor Capacity

Vaccination Strategies for Patients with B-CLL.

An Improved, Non-Viral Approach for Production of hCD40L + B-CLL Cells for Cancer Immunotherapy.

A Practical Approach for Achieving Clinical Immunotherapy of CLL with hCD40L- and hIL-2-Expressing Autologous Tumor Cells.

Email alerts

ASH Publications

American Society of Hematology

Preclinical Evaluation for Engraftment of Gene-Edited CD34+ Cells with a Sickle Cell Disease Mutation in a Rhesus Transplantation Model

Gene Editing and mRNA-Based Therapy: Two Complementary Therapeutic Approaches for the Treatment of Patients with Xmen Disease

A Highly Efficient, Clinically Applicable Transfection Method to Redirect the Specificity of Immune Cells and Enhance Their Anti-Tumor Capacity

Vaccination Strategies for Patients with B-CLL.

An Improved, Non-Viral Approach for Production of hCD40L + B-CLL Cells for Cancer Immunotherapy.

A Practical Approach for Achieving Clinical Immunotherapy of CLL with hCD40L- and hIL-2-Expressing Autologous Tumor Cells.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only